drugset / Trial / NCT00991250
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to elucidate whether SentoClone® gives improved treatment responses in patients with advanced malignant melanoma in comparison to established reference treatment(s).
Timeline
- Start
- 2009-10
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dacarbazine | Small molecule | — | Intravenous |
| Subject | SentoClone® | Cell therapy | 100 ml | Intravenous |
| Subject | SentoClone® | Cell therapy | 200 ml | Intravenous |
| Comparator | Temozolomide | Small molecule | — | Oral |